Stereotactic body radiotherapy for prostate cancer: A preliminary report
Authors:
- 20 September 2012
- journal article
- research article
- Published by Wiley in Asia-Pacific Journal of Clinical Oncology
- Vol. 10 (2) , e46-e53
Abstract
Aims: We report the results of a retrospective study of stereotactic body radiotherapy (SBRT) using a Cyberknife for prostate cancer.Methods: In all 29 patients were treated with hypofractionated SBRT using a Cyberknife at median 36 Gy in five fractions. All the patients were treated with a radical aim. Prostate‐specific antigen (PSA) was evaluated at baseline and after radiotherapy. Acute (≤3 months) and late (>3 months) urinary and rectal toxicities were recorded according to the CTCAE version 4.0.Results: The median duration of follow up was 41 months. PSA values decreased in a time‐dependent way. The median PSA nadir was 0.329 ng/mL, achieved after a median of 23 months’ follow up. Two patients had a PSA failure according to the definition of nadir + 2 ng/mL. Eight patients (28%) had a benign PSA bounce at median 9 months after radiotherapy. CTCAE Grade 2 and 3 late urinary toxicities were reported in 3 and 3%, respectively. One patient had exacerbated urinary symptoms and received an operation. There were no severe late rectal toxicities.Conclusions: The preliminary findings of our study suggest SBRT is feasible for prostate cancer treatment. Further studies with more patients and longer follow‐up duration are required.Keywords
This publication has 25 references indexed in Scilit:
- Hypofractionated Versus Conventionally Fractionated Radiotherapy for Prostate Carcinoma: Final Results of Phase III Randomized TrialInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Phase I Dose-Escalation Study of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate CancerJournal of Clinical Oncology, 2011
- Prostate-specific Antigen Bounce After Intensity-modulated Radiotherapy for Prostate CancerUrology, 2010
- Stereotactic body radiotherapy for organ-confined prostate cancerBMC Urology, 2010
- Prostate-specific Antigen Bounce After Prostate Brachytherapy: Review of a Confusing PhenomenonUrology, 2009
- Phase I/II Study of a Five-fraction Hypofractionated Accelerated Radiotherapy Treatment for Low-risk Localised Prostate Cancer: Early Results of pHART3Clinical Oncology, 2008
- Guideline for the Management of Clinically Localized Prostate Cancer: 2007 UpdateJournal of Urology, 2007
- Is the α/β Value for Prostate Tumours Low Enough to be Safely Used in Clinical Trials?Clinical Oncology, 2007
- Phase II study of a four-week hypofractionated external beam radiotherapy regimen for prostate cancer: Report on acute toxicityRadiotherapy and Oncology, 2006
- Rising prostate cancer rates in South KoreaThe Prostate, 2006